AMLX revenueQ4 2025$0
- FY YoY
- -100.0%
AMLX revenue was $0 in fiscal Q4 2025 (ended Dec 31, 2025), compared with -$665.0K a year earlier. For the full fiscal 2025 it was $0, down 100.0% from fiscal 2024.
Amylyx Pharmaceuticals Inc. (AMLX) financials
For fiscal 2025 (ended Dec 31, 2025), Amylyx Pharmaceuticals Inc. reported $0 of revenue and -$144.74M of net income.
- Revenue, FY2025
- $0
- Revenue growth, YoY
- -100.0%
- Net income, FY2025
- -$144.74M
- Free cash flow, FY2025
- -$123.48M
- EPS, diluted, FY2025
- -$1.53
- Cash
- $240.09M
- Market cap
- $3.88B
FY2021FY2025
FY2021FY2025
FY2021FY2025
AMLX revenue and earnings growth
AMLX net incomeQ3 2026-$45.49M
AMLX net income was -$45.49M in fiscal Q3 2026 (ended Sep 30, 2026), compared with -$34.39M a year earlier. For the full fiscal 2025 it was -$144.74M, compared with -$301.74M in fiscal 2024.
AMLX EPSQ3 2026-$0.38
AMLX diluted EPS was -$0.38 in fiscal Q3 2026 (ended Sep 30, 2026), compared with -$0.37 a year earlier. For the full fiscal 2025 it was -$1.53, compared with -$4.43 in fiscal 2024.
AMLX free cash flowQ3 2026-$33.70M
AMLX free cash flow was -$33.70M in fiscal Q3 2026 (ended Sep 30, 2026), compared with -$30.39M a year earlier. For the full fiscal 2025 it was -$123.48M, compared with -$167.80M in fiscal 2024.
Income statement
| Line item | Dec 31, 2025 | Dec 31, 2024 | Dec 31, 2023 | Dec 31, 2022 | Dec 31, 2021 |
|---|---|---|---|---|---|
| Revenue | $0 | $87.37M | $380.79M | $22.23M | $285.0K |
| Cost of revenue | $0 | $5.95M | $25.44M | $2.99M | - |
| Gross profit | $0 | $81.42M | $355.35M | $19.24M | - |
| Research and development | $90.40M | $104.08M | $128.19M | $93.45M | $44.04M |
| Selling, general and admin | $62.89M | $114.33M | $188.36M | $127.13M | $38.93M |
| Operating income | -$153.29M | -$314.73M | $38.80M | -$201.34M | -$82.69M |
| Pre-tax income | -$144.69M | -$302.14M | $54.30M | -$197.60M | -$87.93M |
| Income tax | $46.0K | -$393.0K | $5.03M | $774.0K | - |
| Net income | -$144.74M | -$301.74M | $49.27M | -$198.38M | -$87.93M |
| EPS, basic | -$1.53 | -$4.43 | $0.73 | -$3.39 | -$13.35 |
| EPS, diluted | -$1.53 | -$4.43 | $0.70 | -$3.39 | -$13.35 |
| Diluted shares | 94.6M | 68.1M | 70.0M | 58.5M | 6.6M |
Balance sheet
| Line item | Dec 31, 2025 | Dec 31, 2024 | Dec 31, 2023 | Dec 31, 2022 | Dec 31, 2021 |
|---|---|---|---|---|---|
| Cash and equivalents | $226.65M | $77.39M | $170.20M | $62.53M | $50.19M |
| Short-term investments | $90.33M | $99.11M | $201.16M | $284.42M | $45.93M |
| Receivables | $88.0K | $447.0K | $40.05M | $15.31M | - |
| Inventory | - | - | $38.32M | $9.77M | - |
| Current assets | $323.67M | $189.43M | $464.67M | $382.13M | $104.95M |
| Total assets | $332.64M | $193.63M | $517.45M | $391.45M | $105.61M |
| Current liabilities | $22.69M | $28.41M | $82.04M | $46.61M | $17.40M |
| Total liabilities | $27.39M | $28.87M | $84.02M | $50.85M | $17.43M |
| Shareholders' equity | $305.26M | $164.76M | $433.43M | $340.61M | -$151.17M |
Cash flow
| Line item | Dec 31, 2025 | Dec 31, 2024 | Dec 31, 2023 | Dec 31, 2022 | Dec 31, 2021 |
|---|---|---|---|---|---|
| Operating cash flow | -$123.34M | -$167.65M | $11.92M | -$179.87M | -$74.80M |
| Capital expenditures | $138.0K | $157.0K | $1.24M | $2.53M | $353.0K |
| Free cash flow | -$123.48M | -$167.80M | $10.68M | -$182.40M | -$75.15M |
| Investing cash flow | $14.04M | $75.65M | $92.05M | -$238.99M | -$46.41M |
| Financing cash flow | $257.03M | $348.0K | $3.54M | $431.79M | $158.51M |
| Stock-based compensation | $27.64M | $33.04M | $37.16M | $21.71M | $3.14M |
Key ratios
| Line item | Dec 31, 2025 | Dec 31, 2024 | Dec 31, 2023 | Dec 31, 2022 | Dec 31, 2021 |
|---|---|---|---|---|---|
| Revenue growth, YoY | -100.0% | -77.1% | 1612.9% | 7700.0% | - |
| Gross margin | - | 93.2% | 93.3% | 86.5% | - |
| Operating margin | - | -360.2% | 10.2% | -905.7% | -29013.3% |
| Net margin | - | -345.4% | 12.9% | -892.4% | -30853.0% |
| Free cash flow margin | - | -192.1% | 2.8% | -820.5% | -26369.1% |
| Return on equity | -47.4% | -183.1% | 11.4% | -58.2% | - |
| Return on assets | -43.5% | -155.8% | 9.5% | -50.7% | -83.3% |
| Current ratio | 14.27 | 6.67 | 5.66 | 8.20 | 6.03 |
Income statement
| Line item | Sep 30, 2026 | Jun 30, 2026 | Mar 31, 2026 | Dec 31, 2025 | Sep 30, 2025 | Jun 30, 2025 | Mar 31, 2025 | Dec 31, 2024 | Sep 30, 2024 | Jun 30, 2024 | Mar 31, 2024 | Dec 31, 2023 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | - | - | - | $0 | $0 | $0 | $0 | -$665.0K | $416.0K | -$1.02M | $88.64M | $108.45M |
| Cost of revenue | - | - | - | $0 | $0 | $0 | $0 | $0 | $0 | $8.0K | $5.95M | $9.36M |
| Gross profit | - | - | - | $0 | $0 | $0 | $0 | -$665.0K | $416.0K | -$1.03M | $82.70M | $99.09M |
| Research and development | $28.35M | $23.77M | $27.61M | $21.21M | $19.86M | $27.22M | $22.12M | $22.89M | $21.24M | $23.35M | $36.61M | $44.91M |
| Selling, general and admin | $21.31M | $21.93M | $16.17M | $15.39M | $16.17M | $15.64M | $15.68M | $17.10M | $17.83M | $21.65M | $57.76M | $52.24M |
| Operating income | -$49.66M | -$45.69M | -$43.78M | -$36.60M | -$36.03M | -$42.86M | -$37.80M | -$40.65M | -$75.66M | -$76.29M | -$122.13M | $1.93M |
| Pre-tax income | - | - | - | -$32.95M | -$34.39M | -$41.44M | -$35.91M | -$38.18M | -$72.70M | -$72.70M | -$118.55M | $6.48M |
| Income tax | - | - | - | $46.0K | $0 | $0 | $0 | -$635.0K | $0 | $0 | $242.0K | $1.75M |
| Net income | -$45.49M | -$43.42M | -$41.28M | -$33.00M | -$34.39M | -$41.44M | -$35.91M | -$37.55M | -$72.70M | -$72.70M | -$118.79M | $4.73M |
| EPS, basic | -$0.38 | -$0.39 | -$0.37 | -$0.28 | -$0.37 | -$0.46 | -$0.42 | -$0.54 | -$1.07 | -$1.07 | -$1.75 | $0.07 |
| EPS, diluted | -$0.38 | -$0.39 | -$0.37 | -$0.28 | -$0.37 | -$0.46 | -$0.42 | -$0.54 | -$1.07 | -$1.07 | -$1.75 | $0.07 |
| Diluted shares | 118.9M | 111.2M | 110.6M | - | 93.3M | 89.1M | 85.7M | - | 68.1M | 68.0M | 67.9M | - |
Balance sheet
| Line item | Sep 30, 2026 | Jun 30, 2026 | Mar 31, 2026 | Dec 31, 2025 | Sep 30, 2025 | Jun 30, 2025 | Mar 31, 2025 | Dec 31, 2024 | Sep 30, 2024 | Jun 30, 2024 | Mar 31, 2024 | Dec 31, 2023 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Cash and equivalents | $240.09M | $49.33M | $229.14M | $226.65M | $225.18M | $58.09M | $59.76M | $77.39M | $71.84M | $75.00M | $170.55M | $170.20M |
| Short-term investments | $528.04M | $201.43M | $50.63M | $90.33M | $118.81M | $122.74M | $144.30M | $99.11M | $162.56M | $234.81M | $202.74M | $201.16M |
| Receivables | - | - | - | $88.0K | $132.0K | $103.0K | $300.0K | $447.0K | $1.73M | $4.09M | $20.35M | $40.05M |
| Inventory | - | - | - | - | - | - | - | - | - | - | - | $38.32M |
| Current assets | $778.86M | $256.34M | $285.02M | $323.67M | $353.38M | $186.89M | $216.14M | $189.43M | $245.26M | $326.72M | $410.53M | $464.67M |
| Total assets | $786.79M | $264.56M | $293.60M | $332.64M | $362.74M | $194.60M | $219.68M | $193.63M | $250.71M | $332.16M | $417.46M | $517.45M |
| Current liabilities | $29.05M | $21.15M | $15.97M | $22.69M | $25.79M | $21.42M | $17.93M | $28.41M | $53.91M | $70.08M | $91.64M | $82.04M |
| Total liabilities | $33.06M | $25.40M | $20.44M | $27.39M | $30.75M | $26.72M | $18.26M | $28.87M | $54.51M | $70.85M | $93.02M | $84.02M |
| Shareholders' equity | $753.74M | $239.17M | $273.16M | $305.26M | $332.00M | $167.88M | $201.42M | $164.76M | $196.20M | $261.31M | $324.44M | $433.43M |
Cash flow
| Line item | Sep 30, 2026 | Jun 30, 2026 | Mar 31, 2026 | Dec 31, 2025 | Sep 30, 2025 | Jun 30, 2025 | Mar 31, 2025 | Dec 31, 2024 | Sep 30, 2024 | Jun 30, 2024 | Mar 31, 2024 | Dec 31, 2023 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Operating cash flow | -$33.67M | -$31.42M | -$36.88M | -$27.90M | -$30.37M | -$25.25M | -$39.82M | -$59.01M | -$41.57M | -$66.58M | -$489.0K | $13.55M |
| Capital expenditures | $25.0K | - | - | $86.0K | $24.0K | $17.0K | $11.0K | $20.0K | -$19.0K | $89.0K | $67.0K | $356.0K |
| Free cash flow | -$33.70M | - | - | -$27.99M | -$30.39M | -$25.27M | -$39.84M | -$59.03M | -$41.59M | -$66.67M | -$556.0K | $13.20M |
| Investing cash flow | -$325.67M | -$149.80M | $36.26M | $29.47M | $5.24M | $22.99M | -$43.66M | $64.98M | $38.82M | -$28.96M | $819.0K | $20.93M |
| Financing cash flow | $550.16M | $1.48M | $3.22M | -$208.0K | $191.61M | -$31.0K | $65.66M | $110.0K | $80.0K | $27.0K | $131.0K | $230.0K |
| Stock-based compensation | $10.37M | $8.32M | $6.12M | $6.39M | $7.08M | $7.35M | $6.83M | $6.74M | $6.80M | $9.57M | $9.92M | $9.53M |
Key ratios
| Line item | Sep 30, 2026 | Jun 30, 2026 | Mar 31, 2026 | Dec 31, 2025 | Sep 30, 2025 | Jun 30, 2025 | Mar 31, 2025 | Dec 31, 2024 | Sep 30, 2024 | Jun 30, 2024 | Mar 31, 2024 | Dec 31, 2023 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue growth, YoY | - | - | - | - | -100.0% | - | -100.0% | -100.6% | -99.6% | -101.0% | 24.1% | - |
| Gross margin | - | - | - | - | - | - | - | - | 100.0% | - | 93.3% | 91.4% |
| Operating margin | - | - | - | - | - | - | - | - | -18187.7% | - | -137.8% | 1.8% |
| Net margin | - | - | - | - | - | - | - | - | -17476.9% | - | -134.0% | 4.4% |
| Free cash flow margin | - | - | - | - | - | - | - | - | -9997.4% | - | -0.6% | 12.2% |
| Current ratio | 26.81 | 12.12 | 17.85 | 14.27 | 13.70 | 8.72 | 12.05 | 6.67 | 4.55 | 4.66 | 4.48 | 5.66 |
Source: XBRL data Amylyx Pharmaceuticals Inc. files with the SEC, latest filing dated Nov 5, 2026 (see filings on SEC EDGAR). Provided for information only, not investment advice. Check the filing before relying on a number.
* Worked out from the filings rather than stated in them: Q4 is the full year less the first nine months.
Per-share figures are as filed. The filings show no stock split in these periods.
EPS growth is left out where the share count moved enough to suggest a split the filings do not show. Growth rates need a positive starting figure. CAGR is compound annual growth between fiscal years. The CSV holds every period on file, in full figures, from the same SEC filings.
AMLX peers
| Company | Revenue | Growth | Net income | Net margin | Market cap |
|---|---|---|---|---|---|
| AMLX | $0 | -100.0% | -$144.74M | - | $3.88B |
| LLY | $86.46B | +45.5% | $27.58B | 31.9% | $1.33T |
| JNJ | $99.33B | +7.8% | $16.09B | 16.2% | $679.13B |
| ABBV | $66.01B | +10.7% | $10.34B | 15.7% | $518.44B |
| MRK | $67.38B | +4.9% | $2.45B | 3.6% | $366.73B |
| NVS | $54.53B | +8.4% | $13.98B | 25.6% | $312.35B |
| AZN | $58.74B | +8.6% | $10.22B | 17.4% | $293.69B |
| ABT | $48.23B | +10.0% | $4.70B | 9.7% | $191.40B |
| NVO | DKK 309.06B | +6.4% | DKK 102.43B | 33.1% | $183.23B |
AMLX FAQ
8 questionsWhat is AMLX revenue?
Amylyx Pharmaceuticals Inc. (AMLX) reported $0 of revenue for fiscal 2025 (ended Dec 31, 2025). That is down 100.0% from the year before.Is AMLX profitable?
No. Amylyx Pharmaceuticals Inc. reported a net loss of $144.74M for fiscal 2025 (ended Dec 31, 2025).How much cash and debt does AMLX have?
Amylyx Pharmaceuticals Inc. reported $240.09M in cash and cash equivalents on its most recent balance sheet in SEC filings.How fast is AMLX revenue growing?
Amylyx Pharmaceuticals Inc.'s revenue changed -100.0% in fiscal 2025, to $0.What is AMLX free cash flow?
Amylyx Pharmaceuticals Inc. generated -$123.48M of free cash flow for fiscal 2025 (ended Dec 31, 2025), which is operating cash flow of -$123.34M less capital expenditures.What is AMLX earnings per share?
Diluted earnings per share were -$1.53 for fiscal 2025 (ended Dec 31, 2025), from SEC filings, restated for any stock split those filings show.When did AMLX last report financial results?
The latest statements here come from Amylyx Pharmaceuticals Inc.'s 10-Q filed on Nov 5, 2026, covering the period ended Sep 30, 2026.Where does this AMLX financial data come from?
Quantisnow builds these statements from the structured XBRL data Amylyx Pharmaceuticals Inc. files with the SEC. It is provided for information only and is not investment advice.